NI201100166A - Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa - Google Patents

Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa

Info

Publication number
NI201100166A
NI201100166A NI201100166A NI201100166A NI201100166A NI 201100166 A NI201100166 A NI 201100166A NI 201100166 A NI201100166 A NI 201100166A NI 201100166 A NI201100166 A NI 201100166A NI 201100166 A NI201100166 A NI 201100166A
Authority
NI
Nicaragua
Prior art keywords
benzofuranil
derivatives used
glucokinase
glucokinase inhibitors
inhibitors
Prior art date
Application number
NI201100166A
Other languages
English (en)
Inventor
Lai Ling Anthony
Allen Pfefferkorn Jeffrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42124287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NI201100166A publication Critical patent/NI201100166A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula (I) que actúan como activadores de glucocinasa; composiciones farmacéuticas de los mismos; y procedimientos para tratar enfermedades, trastornos o afecciones mediadas por glucocinasa.
NI201100166A 2009-03-11 2011-09-02 Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa NI201100166A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15909909P 2009-03-11 2009-03-11

Publications (1)

Publication Number Publication Date
NI201100166A true NI201100166A (es) 2012-01-23

Family

ID=42124287

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100166A NI201100166A (es) 2009-03-11 2011-09-02 Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa

Country Status (38)

Country Link
US (2) US8455496B2 (es)
EP (2) EP2604604A1 (es)
JP (1) JP5086480B2 (es)
KR (1) KR101295937B1 (es)
CN (1) CN102388038B (es)
AP (1) AP3179A (es)
AR (1) AR075729A1 (es)
AU (1) AU2010222589B2 (es)
BR (1) BRPI1013246B1 (es)
CA (1) CA2754681C (es)
CL (1) CL2011002185A1 (es)
CO (1) CO6430427A2 (es)
CR (1) CR20110467A (es)
CU (1) CU24036B1 (es)
DK (1) DK2406253T3 (es)
DO (1) DOP2011000279A (es)
EA (1) EA018894B1 (es)
EC (1) ECSP11011306A (es)
ES (1) ES2427279T3 (es)
GE (1) GEP20156239B (es)
HK (1) HK1164281A1 (es)
HR (1) HRP20130661T1 (es)
IL (1) IL214942A (es)
MA (1) MA33119B1 (es)
MY (1) MY151246A (es)
NI (1) NI201100166A (es)
NZ (1) NZ595024A (es)
PE (1) PE20120668A1 (es)
PL (1) PL2406253T3 (es)
PT (1) PT2406253E (es)
RS (1) RS52903B (es)
SI (1) SI2406253T1 (es)
TN (1) TN2011000454A1 (es)
TW (1) TWI383981B (es)
UA (1) UA99882C2 (es)
UY (1) UY32480A (es)
WO (1) WO2010103437A1 (es)
ZA (1) ZA201106632B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547679B1 (en) 2010-03-19 2015-11-04 Pfizer Inc 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
AU2011322117B2 (en) 2010-10-29 2015-01-22 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
CU24164B1 (es) 2011-04-22 2016-03-31 Pfizer Inhibidores sustituidos de acetil-coa carboxilasa
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
EP2734503B1 (en) 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013068875A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. 2-thiopyrimidinones
US9296745B2 (en) 2012-04-06 2016-03-29 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
CN106103425A (zh) 2014-03-17 2016-11-09 辉瑞公司 用于治疗代谢及相关病症的二酰甘油酰基转移酶2抑制剂
ES2718552T3 (es) 2014-04-04 2019-07-02 Pfizer Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
CN104387348A (zh) * 2014-10-27 2015-03-04 湖南华腾制药有限公司 一种苯并呋喃衍生物的制备方法
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
WO2016178113A1 (en) 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones
CA2987179C (en) 2015-05-29 2020-08-25 Pfizer Inc. Heterocyclic compounds as inhibitors of vanin-1 enzyme
WO2016203347A1 (en) 2015-06-17 2016-12-22 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
US20180230127A1 (en) 2015-08-13 2018-08-16 Pfizer Inc. Bicyclic-Fused Heteroaryl Or Aryl Compounds
MX2018002402A (es) 2015-08-27 2018-04-11 Pfizer Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
SG11201804363UA (en) 2015-12-29 2018-07-30 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
WO2019228366A1 (zh) * 2018-05-31 2019-12-05 华领医药技术（上海）有限公司 含葡萄糖激酶激活剂和α-葡萄糖苷酶抑制剂的药物组合、组合物和制剂及其制备方法和用途
KR102614808B1 (ko) 2018-08-31 2023-12-19 화이자 인코포레이티드 Nash/nafld 및 관련 질환의 치료를 위한 조합물
US20210338776A1 (en) * 2018-09-06 2021-11-04 Yale University Treatments against mosquito-borne viruses based on mosquito salivary gland proteins
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2020261144A1 (en) 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CA3186348A1 (en) 2020-06-09 2021-12-16 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
IL312296A (en) 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
RU2105005C1 (ru) 1992-07-03 1998-02-20 Кумиай Кемикал Индастри Ко., Лтд. Конденсированное гетероциклическое производное, способ его получения и гербицидное средство
KR100381584B1 (ko) 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CA2202056A1 (en) 1994-10-13 1996-04-25 Mark A. Dombroski Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists
AU696890B2 (en) 1994-10-13 1998-09-24 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
BR9709113A (pt) 1996-05-20 1999-08-03 Darwin Discovery Ltd Benzofurano carboxamidas e seu uso terapêutico
DE69717827T2 (de) 1996-08-19 2003-09-04 Altana Pharma Ag Benzofuran-4-carboxamide
WO1999040085A1 (en) 1998-02-09 1999-08-12 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
JP4754693B2 (ja) 1999-01-22 2011-08-24 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４関連障害を処置するアシル誘導体
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US6670380B2 (en) 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
BR0115999A (pt) 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
CN1633297A (zh) 2001-02-28 2005-06-29 麦克公司 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US7129225B2 (en) 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
US7067540B2 (en) 2002-02-14 2006-06-27 Pharmacia Corporation Substituted pyridinones
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
JP2005538047A (ja) 2002-05-03 2005-12-15 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ボンベシンアンタゴニスト
BR0311707A (pt) 2002-06-13 2005-03-15 Du Pont Composto, composição e método de controle de pelo menos uma praga invertebrada
JP4302967B2 (ja) * 2002-11-18 2009-07-29 パイオニア株式会社 楽曲検索方法、楽曲検索装置及び楽曲検索プログラム
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
CN100378094C (zh) * 2003-02-13 2008-04-02 万有制药株式会社 2-吡啶甲酰胺衍生物
JP4400563B2 (ja) 2003-02-13 2010-01-20 萬有製薬株式会社 新規２−ピリジンカルボキサミド誘導体
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
JP4432901B2 (ja) 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
AU2004259703A1 (en) 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
CA2533747C (en) 2003-08-01 2012-11-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
CN1993347A (zh) 2004-07-29 2007-07-04 默克公司 钾通道抑制剂
EP1786783A1 (en) 2004-09-01 2007-05-23 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
MX2007007480A (es) 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de cromano y su uso como ligandos del receptor 5-ht.
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
JP2009532375A (ja) 2006-03-30 2009-09-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
DK2463283T3 (da) * 2006-04-20 2014-08-18 Pfizer Prod Inc Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
CN101679365A (zh) 2007-06-08 2010-03-24 艾德维纳斯医疗私人有限公司 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド

Also Published As

Publication number Publication date
IL214942A (en) 2015-10-29
PL2406253T3 (pl) 2013-10-31
AU2010222589B2 (en) 2012-08-16
UY32480A (es) 2010-10-29
PT2406253E (pt) 2013-09-11
KR20110123288A (ko) 2011-11-14
EP2406253A1 (en) 2012-01-18
AU2010222589A1 (en) 2011-09-22
EA018894B1 (ru) 2013-11-29
AP2011005882A0 (en) 2011-10-31
CU24036B1 (es) 2014-10-30
CO6430427A2 (es) 2012-04-30
ZA201106632B (en) 2012-05-30
NZ595024A (en) 2013-01-25
CU20110168A7 (es) 2012-02-15
US8455496B2 (en) 2013-06-04
MY151246A (en) 2014-04-30
EA201190158A1 (ru) 2012-04-30
US20100234285A1 (en) 2010-09-16
HRP20130661T1 (en) 2013-08-31
IL214942A0 (en) 2011-11-30
TWI383981B (zh) 2013-02-01
CN102388038B (zh) 2014-04-23
CL2011002185A1 (es) 2012-02-03
AP3179A (en) 2015-03-31
CR20110467A (es) 2011-10-07
SI2406253T1 (sl) 2013-09-30
UA99882C2 (uk) 2012-10-10
BRPI1013246B1 (pt) 2019-10-01
CA2754681C (en) 2014-01-07
AR075729A1 (es) 2011-04-20
JP5086480B2 (ja) 2012-11-28
CN102388038A (zh) 2012-03-21
PE20120668A1 (es) 2012-06-01
DK2406253T3 (da) 2013-08-12
TN2011000454A1 (fr) 2013-03-27
ECSP11011306A (es) 2011-10-31
GEP20156239B (en) 2015-01-26
JP2012520286A (ja) 2012-09-06
ES2427279T3 (es) 2013-10-29
MA33119B1 (fr) 2012-03-01
BRPI1013246A2 (pt) 2016-04-05
KR101295937B1 (ko) 2013-08-14
EP2406253B1 (en) 2013-07-03
CA2754681A1 (en) 2010-09-16
WO2010103437A1 (en) 2010-09-16
DOP2011000279A (es) 2011-10-15
US8735396B2 (en) 2014-05-27
EP2604604A1 (en) 2013-06-19
US20130252973A1 (en) 2013-09-26
TW201036961A (en) 2010-10-16
HK1164281A1 (en) 2012-09-21
RS52903B (en) 2014-02-28

Similar Documents

Publication Publication Date Title
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
CR20110103A (es) Heteroarilos sustituidos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
CO6551721A2 (es) Moduladores de cinasa novedosos
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CR20110326A (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
UY32848A (es) Compuestos heterocíclicos de oxima
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
UY32385A (es) Amidas de pirazinona sustituida
CL2015003037A1 (es) Derivados de triazina
CL2012000461A1 (es) Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer.
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa